CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 77 enrolled
Drug / intervention
Sodium Glycididazole +1 moredrug
Likely dose
Sodium Glycididazole 700mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02721563
NCT02721563Phase 4Completed
CompareCT.gov

A Perspective Random Trial of Sodium Glycididazole Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma

Shandong Cancer Hospital and Institute·interventional·Posted Mar 29, 2016·Updated Oct 11, 2019

In Brief

A Phase 4 clinical trial evaluating Sodium Glycididazole and Placebo for Esophageal Neoplasms. Completed, enrolled 77 participants across 10 sites.

Detailed Summary

This is a perspective, multicenter,randomized controlled trial to evaluate the efficacy and safety of treatment with CMNa combined with concurrent chemoradiotherapy in patients with locally advanced squamous cell esophageal carcinoma . Analyses of primary objective (ORR) will be done as defined in the protocol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Neoplasms
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 29, 2016
Enrollment StartFeb 25, 2016
Primary CompletionJun 10, 2018
Study CompletionJun 30, 2018
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 10.3 years ago

Interventions

Sodium Glycididazoledrug

Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.

Placebodrug

Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.